5-phenyl 2-methyl oxazole-3-ethanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-phenyl 2-methyl oxazole-3-ethanol
• 英文别名: 2-(2-methyl-5-phenyl-2H-1,3-oxazol-3-yl)ethanol
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: HQQDITFEEQDNDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  aqueous LiOH 、 5-phenyl 2-methyl oxazole-3-ethanol 、 4-羟基苯乙酸甲酯 生成 苯乙酸
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
  申请人：——

  公开号：US20030092736A1

  公开（公告）日：2003-05-15

  Compounds are provided which have the structure 1 wherein Q is C or N; R 2a , R 2b , R 2c , X 1 to X 7 , R 1 , R 2 , R 3 , R 3a , R 4 , A, Y, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. The present invention further provides a method for treating obesity and dyslipidemia in mammals including humans through simultaneous inhibition of peroxisome proliferator activated receptor-&ggr; (PPAR&ggr;) and stimulation of peroxisome proliferator activated receptor-&agr; (PPAR&agr;).

  提供了具有以下结构1的化合物，其中Q为C或N; R2a，R2b，R2c，X1至X7，R1，R2，R3，R3a，R4，A，Y，m和n如本文所定义，这些化合物可用作抗糖尿病，降脂和抗肥胖剂。本发明还提供了一种通过同时抑制过氧化物酶体增殖物活化受体-γ（PPARγ）和刺激过氧化物酶体增殖物活化受体-α（PPARα）治疗哺乳动物包括人类的肥胖和血脂异常的方法。
• SUBSTITUTED AZOLE ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD
  申请人：Bristol-Myers Squibb Company

  公开号：EP1390363A2

  公开（公告）日：2004-02-25
• US6967212B2
  申请人：——

  公开号：US6967212B2

  公开（公告）日：2005-11-22
• [EN] SUBSTITUTED AZOLE ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD<br/>[FR] DERIVES ACIDES D'AZOLE SUBSTITUE UTILES COMME AGENTS ANTIDIABETIQUES ET AGENTS CONTRE L'OBESITE ET PROCEDE APPARENTE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002096358A2

  公开（公告）日：2002-12-05

  Compounds are provided which have the structure: (formula I); wherein Q is C or N; R?2a, R2b, R2c, X¿1 to X7, R?1, R2, R3, R3a, R4¿, A, Y, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. The present invention further provides a method for treating obesity and dyslipidemia in mammals including humans through simultaneous inhibition of peroxisome proliferator activated receptor-η (PPARη) and stimulation of peroxisome proliferator activated receptor-α (PPARα).